Medical offset for Rx costs remains elusive

Lee, Karen
May 2002
Employee Benefit News;May2002, Vol. 16 Issue 6, p45
Focuses on the costs of prescription drugs in the U.S. Increase in outpatient prescription drugs spending between 2000 and 2001; Result of a study conducted by Tufts University researcher Joshua Cohen on prescription drug spending; Details of a research conducted by Frank Lichtenberg, professor of finance and economics at Colombia University, regarding the use of newer prescription medication.


Related Articles

  • New drugs prolong life.  // BRW;4/17/2008, Vol. 30 Issue 15, p13 

    The article highlights a research which claims that taking the latest drugs allow people to live longer. According to Columbia Business School professor Frank Lichtenberg, using new medicines instead of older ones also cuts costs in the medical system as a whole both in the United States and...

  • I Want a New Drug. Bailey, Ronald // Reason;Feb2009, Vol. 40 Issue 9, p7 

    The article focuses on the effectivity of newer drugs to reduce other medical expenditures in the U.S. Columbia University economist Frank Lichtenberg found out that U.S. states adopted new drugs rapidly had the smallest increase in disability rates. In addition, he discovered that newer...

  • US formulary inclusion more likely if drug's value established.  // PharmacoEconomics & Outcomes News;9/25/2004, Issue 462, p7 

    Reports that health plans in the U.S. are increasingly taking cost into account when deciding which new drugs to include for third-party reimbursement, according to a study conducted by the Tufts Center. Significant findings of the research; Comments from Joshua Cohen, author of the study.

  • Making Personalized Medicine A Reality Proves Challenging. Serebrov, Mari // BioWorld Today;8/3/2011, Vol. 22 Issue 149, p1 

    The article focuses on a report by the Tufts Center for the Study of Drug Development (CSDD) which revealed the slow growth of the number of drugs and biologics with companion diagnostics approved for use in the U.S. According to Joshua Cohen, senior research fellow at Tufts CSDD, reimbursement...

  • Drug utilization depends as much on price as it does on marketing.  // Drug Store News;12/14/2009, Vol. 31 Issue 15, p54 

    The article reports on several research studies, according to which lower price of a drug, after its branded version loses patent protection, may not translate into its greater utilization. According to economists, Frank Lichtenberg, and Gautier Duflos, decreased utilization of a branded drug...

  • The respective roles of the public and private sectors in pharmaceutical innovation.  // Biomedical Market Newsletter;12/21/2011, Vol. 21, p1 

    The article focuses on a new research led by the Columbia Business School researchers including Frank Lichtenberg, Courtney C. Brown, and Bhaven Sampat regarding the role of direct and indirect government support in Research and Development of new pharmaceutical drugs. The data reveals that the...

  • Does Better Health Care Mean Higher Costs? Bailey, Ronald // Reason;Feb2010, Vol. 41 Issue 9, p42 

    The article presents an analysis on the role of medical equipment innovation on health care costs and life expectancy in the U.S. Economist Frank Lichtenberg suggests that there is a faster increase on life expectancy for states that have quicker ways in drug usage, better educated doctors and...

  • Companion Prospecting. Agres, Ted // Drug Discovery & Development;Sep2011, Vol. 14 Issue 9, p10 

    The article focuses on the effort of the U.S. Food and Drug Administration (FDA) to start companion diagnostics despite scientific, logistical, and financial barriers. It asserts that companion diagnostics hold great promise for gaining ground personalized medicine permitting drug developers to...

  • Seafood Shoppers Confused by Mercury Warnings. Blank, Christine // SN: Supermarket News;2/19/2007, Vol. 55 Issue 8, p50 

    The article reports on the confusion of seafood consumers concerning the mercury warnings of the U.S. Food and Drug Administration (FDA). According to Joshua Cohen, senior researcher at Tufts University-New England Medical Center, the advisory of the FDA could hurt public health if people do not...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics